Qualigen Therapeutics, Inc. — Director's Dealing 2021

Apr 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Qualigen Therapeutics, Inc. (QLGN)
CIK: 0001460702
Period of Report: 2021-04-20

Reporting Person: Poirier Michael S. (Director, Chairman, CEO & President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-20	Common Stock	P	11005	$1.80	Acquired	11005	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	169202	Direct